Only patients with the diagnosis of SAH, proved by lumbar puncture were taken into this trial. Patients admitted on three days of the working week formed the group who had EACA and patients admitted on two days of the week formed the group who had TEA. The pre-operative treatment and the policy of investigation by angiography and CT scan were similar in the two groups.
haemorrhage was seen in 8 % of these patients and 7 ' of the patients developed delayed ischaemic deficit. The total pre-operative mortality in EACA-group was 11 %. Of 61 patients treated with TEA, 10 % had recurrent haemorrhage and delayed ischaemic deficit occurred in 5 % of the patients. The total pre-operative mortality in TEA-group was 11 0%. No difference was found between the effectiveness and side-effects of these drugs.
The use of anti-fibrinolytic drugs for prevention of early recurrence of subarachnoid haemorrhage is becoming widespread.1-5 The two drugs used for this purpose are epsilon aminocaproic acid and tranexamic acid. Once Only patients with the diagnosis of SAH, proved by lumbar puncture were taken into this trial. Patients admitted on three days of the working week formed the group who had EACA and patients admitted on two days of the week formed the group who had TEA. The pre-operative treatment and the policy of investigation by angiography and CT scan were similar in the two groups.
EACA was given in a dose of 36 g/day, divided in six equal doses. TEA was given in 6 g/day doses, divided into six equal doses. The oral and intravenous doses were the same. Side-effects, such as nausea, vomiting and diarrhoea were noted. Periodical checks for white cell count, platelet count and haemoglobin levels were done. The incidence of deep-venous thrombosis or pulmonary embolus were carefully recorded. The anti-fibrinolytic drug was continued either to the time of surgery or if surgery was not undertaken, until the patient was discharged. This formed the cut-off point for observation of the patients as far as this trial was concerned.
The criteria of the recurrent haemorrhage were (a) clinical (as outlined in our 
